Ascendis to present 2-year navepegritide trial data at ISDS 2026

Ascendis Pharma A/S (Nasdaq: ASND) announced it will present Week 104 data from the ApproaCH pivotal trial of once-weekly TransCon CNP (navepegritide) at the International Skeletal Dysplasia Society annual meeting in Toronto, Canada, running August 26-29, 2026.

The oral presentation, titled "Improved Growth and Physical Functioning in Children with Achondroplasia Treated with Navepegritide in the ApproaCH Trial Open-Label Extension," is scheduled for August 28 and will be delivered by Carlos Bacino, M.D., Professor of Molecular and Human Genetics at Baylor College of Medicine and Texas Children's Hospital.

Ascendis will also display a poster throughout the conference examining a number needed to harm analysis for injection site reactions when indirect treatment comparison is not suitable.

Aimee Shu, Executive Vice President and Chief Medical Officer at Ascendis Pharma, said the long-term data showed "durable improvements in height," as well as improvements in "lower-extremity alignment, body proportionality, spinal canal dimensions, muscle function, and physical functioning – with a safety and tolerability profile similar to placebo and a low rate of injection site reactions."

TransCon CNP is a prodrug of C-type natriuretic peptide administered once weekly. In February 2026, the U.S. Food and Drug Administration approved the therapy under the trade name YUVIWEL to increase linear growth in pediatric patients aged two years and older with achondroplasia with open epiphyses. A Marketing Authorisation Application for YUVIWEL is currently under review by the European Medicines Agency, with a regulatory decision anticipated in the fourth quarter of 2026.

Achondroplasia is a rare genetic condition estimated to affect more than 250,000 people worldwide, causing skeletal dysplasia as well as muscular, neurological, and cardiorespiratory complications.

You May Also Be Interested In

• ADARx Pharmaceuticals files for proposed IPO
• Canaccord Starts Kistos Holdings (KIST:LN) at Buy
• JPMorgan Upgrades Whitehaven Coal Ltd. (WHC:AU) (WHITF) to Overweight